Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
Phase 2
12
about 31 years
2–25
1 site in DC
About this study
This trial is testing if daratumumab, given before a bone marrow transplant from an identical sibling donor with alemtuzumab, low dose total body irradiation, and sirolimus, can prevent red blood cell problems in people with anti-donor antibodies. The goal is to achieve similar survival rates as those who have transplants without these antibodies.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Total Body Irradiation
- 2.Take Alemtuzumab
- 3.Take Daratumumab
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
alemtuzumab, daratumumab, sirolimus
injection (Injection), infusion, injection, intravenous
Primary: To determine the event-free survival of children and adolescents with SCD undergoing nonmyeloablative HCT who received 4 doses of pre-HCT daratumumab for donor-directed red blood cell antibodies.
Secondary: To characterize the safety of adding pre-HCT daratumumab to the conditioning regimen, as defined by adverse events grade 3 or greater.
radiation